Clinical impact of down-regulated plasma miR-92a levels in non-hodgkin's lymphoma

评估从非霍奇金淋巴瘤患者获得的血浆中的miR-92 a的临床相关性，因为miR-92 miRNA在淋巴发生中以及淋巴组织中的肿瘤发生中起关键作用。我们评估了血浆miR-92 a值;非霍奇金淋巴瘤修饰的MicroRNA测定，并与健康受试者的结果进行了比较。与健康受试者相比，非霍奇金淋巴瘤患者的血浆miR-92 a值极低。在诊断时，下调的血浆miR-92 a在完全反应期增加，达到正常对照水平，并在复发期再次下调。在非霍奇金淋巴瘤患者中，血浆miR-92 a水平明显降低，表明淋巴循环miR-92 a的差异可能是一个重要的临床问题。血浆miR-92 a值可能是监测淋巴瘤患者，特别是惰性淋巴瘤患者的一种新的生物标志物。

To evaluate the clinical relevance of the miR-92a in plasma obtained from non-Hodgkin's lymphoma patients, because miR-92 miRNA plays a crucial role in lymphogenesis, as well as tumorigenesis in lymphoid tissue. We evaluated plasma miR-92a value; MicroRNA Assays with modifications with non-Hodgkin's lymphoma and compared results with healthy subjects. Plasma miR-92a values in non-Hodgkin's lymphoma were extremely low, compared to healthy subjects. At the time of diagnosis The down-regulated plasma miR-92a increased in the complete response phase, reaching normal control levels, and again becoming down-regulated in the relapse phase. In non-Hodgkin's lymphoma patients, while a decreased level of plasma miR-92a was evident, indicating that the discrepancy lymph circulating miR-92a might be an important clinical issue. The plasma miR-92a value could be a novel biomarker for monitoring lymphoma patients, especially in those with indolent lymphoma.